Saltar al contenido
Merck

Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Investigative ophthalmology & visual science (2014-07-17)
Darryl R Overby, Jacques Bertrand, Ozan-Yüksel Tektas, Alexandra Boussommier-Calleja, Martin Schicht, C Ross Ethier, David F Woodward, W Daniel Stamer, Elke Lütjen-Drecoll
RESUMEN

To determine whether dexamethasone (DEX)-induced ocular hypertension (OHT) in mice mimics the hallmarks of steroid-induced glaucoma (SIG) in humans, including reduced conventional outflow facility (C), increased extracellular matrix (ECM), and myofibroblasts within the outflow pathway. Osmotic mini-pumps were implanted subcutaneously into C57BL/6J mice for systemic delivery of DEX (3-4 mg/kg/d, n = 31 mice) or vehicle (n = 28). IOP was measured weekly by rebound tonometry. After 3 to 4 weeks, mice were euthanized and eyes enucleated for ex vivo perfusion to measure C, for electron microscopy to examine the trabecular meshwork (TM) and Schlemm's canal (SC), or for immunohistochemistry to examine type IV collagen and α-smooth muscle actin. The length of basement membrane material (BMM) was measured along the anterior-posterior extent of SC by electron microscopy. Ultrastructural changes in BMM of DEX-treated mice were compared against archived human SIG specimens. Dexamethasone increased IOP by 2.6 ± 1.6 mm Hg (mean ± SD) over 3 to 4 weeks and decreased C by 52% ± 17% versus controls. Intraocular pressure elevation correlated with decreased C. Dexamethasone treatment led to increased fibrillar material in the TM, plaque-like sheath material surrounding elastic fibers, and myofibroblasts along SC outer wall. The length of BMM underlying SC was significantly increased in mice with DEX and in humans with SIG, and in mice decreased C correlated with increased BMM. Dexamethasone-induced OHT in mice mimics hallmarks of human SIG within 4 weeks of DEX treatment. The correlation between reduced C and newly formed ECM motivates further study using DEX-treated mice to investigate the pathogenesis of conventional outflow obstruction in glaucoma.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Glicerol, ACS reagent, ≥99.5%
Sigma-Aldrich
Glicerol, Molecular Biology, ≥99.0%
Sigma-Aldrich
Glicerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glicerol, ≥99.5%
Sigma-Aldrich
Glicerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Glicerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glicerol, BioUltra, Molecular Biology, anhydrous, ≥99.5% (GC)
Supelco
Glicerol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glicerol, BioXtra, ≥99% (GC)
USP
Glicerol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glicerol, FCC, FG
Sigma-Aldrich
Glicerol, meets USP testing specifications
Supelco
Glicerol, analytical standard
Sigma-Aldrich
Enrofloxacin, ≥99.0%
Supelco
Enrofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Anticuerpo anti-colágeno, tipo IV, Chemicon®, from rabbit
Supelco
Enrofloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
Glicerol, tested according to Ph. Eur., anhydrous
Supelco
Carprofen, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Enrofloxacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Carprofen, VETRANAL®, analytical standard
Enrofloxacin, European Pharmacopoeia (EP) Reference Standard
Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Carprofen, European Pharmacopoeia (EP) Reference Standard
Carprofen for system suitability, European Pharmacopoeia (EP) Reference Standard